Sunil Healthcare Peer Comparison

BSE: 537253

₹79.58

₹-0.16 (-0.20%)

As on 02-Sep-2026IST

Market cap

₹80 Cr

Revenue (TTM)

₹84 Cr

P/E Ratio

22.5

P/B Ratio

1.5

Div. Yield

0 %

Edit

	Sunil Healthcare	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	80	30,951	30,239	28,444	25,690
Revenue (₹ Cr)	84	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	3.56	414.00	288.22	-371.81	387.35
Net Margin (%)	4.16	11.23	14.79	-3.93	26.01
RoE (%)	4.91	8.38	29.77	-3.85	25.18
Price to Earnings	22.52	75.67	104.92	--	66.52
Price-To-Book	1.49	6.15	22.53	3.55	14.89

Income Statement (₹ Cr)

	Sunil Healthcare	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	84.06	3,564.00	1,935.80	9,205.28	1,461.80
Total Income	85.62	3,686.00	1,948.58	9,449.59	1,489.25
Total Expenditure	71.65	2,792.00	1,485.56	8,195.15	919.25
EBITDA	12.41	772.00	450.24	1,010.13	542.56
Depreciation	6.23	226.00	50.83	857.51	37.68
EBIT	6.18	546.00	399.41	152.62	504.88
Interest	6.22	217.00	40.84	342.73	3.77
Other Income	1.55	122.00	12.78	244.31	27.45
Exceptional Items	-0.12	12.00	0.00	-216.88	0.00
Profit before Tax	1.40	463.00	371.35	-162.68	528.56
Provision for Tax	-2.16	49.00	83.14	209.13	141.21
Profit after Tax	3.56	414.00	288.22	-371.81	387.35

	Sunil Healthcare	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	69.60	4,940.00	1,288.82	8,162.62	1,653.56
Minority Interest	0.00	-5.00	0.00	0.00	-1.13
Non-Current Liabilities	28.56	1,712.00	202.03	5,044.14	42.40
Current Liabilities	66.34	1,622.00	835.87	4,758.28	230.82
Total Liabilities	161.94	8,100.00	1,451.43	15,513.53	1,549.26

	Sunil Healthcare	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	56.18	5,343.00	519.60	10,211.52	1,026.85
Current Assets	73.86	2,606.00	1,681.81	7,191.66	881.27
Total Assets	161.94	8,100.00	1,451.43	15,513.53	1,549.26
Total Debt*	68.64	1,859.00	393.17	4,720.27	8.18
Net Current Assets	7.52	984.00	845.94	2,433.38	650.46
Contingent Liabilities	5.06	770.26	12.25	99.76	15.38

	Sunil Healthcare	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	11.52	-22.00	159.18	892.30	118.34
Cash Flow from Investing Activities	-7.70	-783.00	-64.81	-477.46	-223.94
Cash from Financing Activities	-3.87	409.00	-39.81	-440.83	261.12
Net Cash Inflow / Outflow	-0.05	-396.00	54.56	-25.99	155.52

	Sunil Healthcare	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	4.44	4.07	26.97	6.61	20.14
ROE (%)	4.91	8.38	29.77	-3.85	25.18
ROA (%)	2.18	4.94	24.77	-2.21	21.93
EBIT Margin (%)	7.35	15.32	20.63	1.66	34.54
Net Margin (%)	4.16	11.23	14.79	-3.93	26.01
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Sunil Healthcare	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	-0.60	18.37	46.65	0.78	40.90
EBIT Growth (%)	28.78	252.26	62.13	-70.53	124.50
Net Profit Growth (%)	1,845.90	377.85	89.49	-1,383.43	104.15
EPS Growth (%)	1,744.65	1,001.33	78.60	-484.84	42.32
Book Value Growth (%)	-1.26	29.77	42.49	2.28	94.96

	Sunil Healthcare	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	23.75	77.67	103.31	-90.90	66.52
Price / Book Value	1.49	6.15	22.53	3.55	14.89
Dividend Yield (%)	0.00	0.00	0.08	0.00	0.08
EV/EBITDA	11.74	41.99	66.97	32.26	46.98
Market Cap (₹ Cr)	67.23	23,064.69	0.00	29,731.27	19,988.69

	Sunil Healthcare	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	0.22	0.31	0.11	0.53	0.01
Short term debt to equity ratio	0.63	0.11	0.54	0.12	0.02
Current Ratio	1.11	1.61	2.01	1.51	3.82
Quick Ratio	0.83	1.06	1.14	0.87	2.82
Interest Coverage	1.23	3.13	10.09	0.53	141.16

	Sunil Healthcare	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	53.68	16.50	26.28	23.44	24.80
Asset Turnover	0.52	0.43	1.66	0.55	0.83
Receivable days	179.89	60.36	47.59	77.05	90.06
Inventory Days	69.35	64.42	62.58	77.13	61.02
Payable days	74.62	218.94	228.78	173.49	96.06
Cash Conversion Cycle	174.62	-94.15	-118.62	-19.30	55.02

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.